Anxious Depression: Clinical Features and Treatment

被引:51
作者
Rao, Sanjai [1 ,2 ,3 ,4 ]
Zisook, Sidney
机构
[1] Univ Calif San Diego, San Diego, CA 92161 USA
[2] Bristol Myers Squibb, Speakers Bur, Bristol, Avon, England
[3] Eli Lilly & Co, Indianapolis, IN USA
[4] AstraZeneca, London, England
关键词
Major Depressive Disorder; Anxiety Disorder; Generalize Anxiety Disorder; Bupropion; Major Depressive Disorder;
D O I
10.1007/s11920-009-0065-2
中图分类号
R749 [精神病学];
学科分类号
100204 [神经病学];
摘要
Anxious depression has been conceptualized in at least two related but separate ways: 1) major depressive disorder with at least one comorbid Axis I anxiety disorder and 2) major depressive disorder with a high level of anxiety with or without one or more comorbid Axis I anxiety disorders. Using either definition, patients with anxious depression seem to have a more chronic course of illness, an increased incidence of suicidal thoughts and behavior, greater functional and occupational impairment, and poorer response to treatment. Multiple classes of medications are used to treat anxious depression, most commonly first-and second-generation antidepressants, atypical antipsychotics, and benzodiazepines. Certain patients with anxious depression may require lower starting doses, more gradual dose escalations, higher end point doses, longer duration of treatment, and/or early augmentation with other agents. Nonpharmacologic treatments such as targeted psychotherapy and preventative stepped-care approaches also may be effective. Well-conceived, randomized controlled treatment trials are necessary to make further gains in the management of patients with anxious depression.
引用
收藏
页码:429 / 436
页数:8
相关论文
共 47 条
[1]
A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder [J].
Amsterdam, JD .
JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (02) :208-214
[2]
Brown C, 1996, AM J PSYCHIAT, V153, P1293
[3]
Social factors and comorbidity of depressive and anxiety disorders [J].
Brown, GW ;
Harris, TO ;
Eales, MJ .
BRITISH JOURNAL OF PSYCHIATRY, 1996, 168 :50-57
[4]
CLAYTON PJ, 1991, AM J PSYCHIAT, V148, P1512
[5]
DOMSCHKE K, 2008, J PSYCHOPHARMAC 1006
[6]
Dunlop Boadie W, 2008, Prim Care Companion J Clin Psychiatry, V10, P222
[7]
The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients [J].
Farabaugh, A ;
Mischoulon, D ;
Fava, M ;
Wu, SL ;
Mascarini, A ;
Tossani, E ;
Alpert, JE .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2005, 20 (02) :87-91
[8]
Six-year outcome of cognitive behavior therapy for prevention of recurrent depression [J].
Fava, GA ;
Ruini, C ;
Rafanelli, C ;
Finos, L ;
Conti, S ;
Grandi, S .
AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (10) :1872-1876
[9]
Major depressive subtypes and treatment response [J].
Fava, M ;
Uebelacker, LA ;
Alpert, JE ;
Nierenberg, AA ;
Pava, JA ;
Rosenbaum, JF .
BIOLOGICAL PSYCHIATRY, 1997, 42 (07) :568-576
[10]
Anxiety disorders in major depression [J].
Fava, M ;
Rankin, MA ;
Wright, EC ;
Alpert, JE ;
Nierenberg, AA ;
Pava, J ;
Rosenbaum, JF .
COMPREHENSIVE PSYCHIATRY, 2000, 41 (02) :97-102